Revenue operations for agencies: how to productise the offering for healthcare and life sciences in emerging markets
The service design, pricing, and delivery model for running revenue operations as a productised offering inside a services firm. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install revenue operations has to be shaped to that reality from day one.
Revenue operations is one of the highest-margin offerings an agency can add in 2026. It is the function that owns the pipes between marketing, sales, and success, and clients will pay a premium for the discipline they cannot install themselves.
Productise around outcome, not activity. Sell days-to-close and forecast accuracy moving to a defined level in a defined window, not a monthly retainer of vague ops.
Delivery pod: one strategist, one operator, one editor. Fewer people than that risks quality; more than that dilutes margin.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Revenue operations is only useful here when it is pointed at both constraints at once.
Onboarding takes two weeks: diagnosis, list build, trigger definition, kill criteria. Do not ship anything live before the diagnosis is signed off.
Pricing: outcome-linked base plus a monthly ops fee. The base rewards results; the ops fee funds the delivery pod.
Client failure mode: hiring RevOps to fix CRM instead of to own revenue. Write it into the engagement letter as a shared risk, not something you absorb quietly.
The agencies making the most from revenue operations are the ones with the tightest playbook. Documented, versioned, and improved every quarter.
Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing revenue operations deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
RevOps · healthcare · emerging markets — answered
- Does revenue operations work for healthcare and life sciences in emerging markets?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
- How should agencies price revenue operations?
- Outcome-linked base plus a monthly ops fee. Avoid pure retainer.
- What is the minimum delivery pod?
- Strategist, operator, editor. Three roles, not necessarily three headcount at small scale.
- How long is agency onboarding for revenue operations?
- Two weeks: diagnosis, list, trigger, kill criteria.
- What client behaviour breaks the engagement?
- Hiring RevOps to fix CRM instead of to own revenue — bake shared risk into the contract.
- What is the emerging markets-specific pitfall when running revenue operations for healthcare?
- Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.
Growth Broker editorial
Filed under revops · healthcare · emerging markets